How Advancements in Peptide Synthesis Are Enabling Next-Generation Drug Development

A decade ago, peptide drugs were a small corner of the pharmaceutical market. The molecules were hard to make at scale, difficult to purify, and limited by short half-lives that made dosing impractical for most chronic conditions. The pipeline was thin, and the commercial successes were few.

That picture has changed dramatically. The peptide therapeutics market reached $49.68 billion in 2026, according to Mordor Intelligence, with projections pointing toward $70 billion by 2031.

Over 110 peptide drugs have been approved globally. Semaglutide and tirzepatide alone generated tens of billions in combined revenue in 2024. What was once considered a niche modality now sits at the center of drug development strategy across metabolic disease, oncology, and rare disorders.

The question worth asking is: what changed? The answer, in large part, comes down to peptide synthesis.

Synthesis Breakthroughs That Made Commercial Peptides Viable

The core manufacturing method for therapeutic peptides, solid-phase peptide synthesis, has been around since the 1960s. The chemistry itself isn't new. What changed is the set of tools that make it work for molecules that would have been impractical to produce even 10 years ago.

Secondary structure disruptors like pseudoproline dipeptides and Dmb/Hmb backbone-protecting amino acids solved one of the oldest problems in peptide synthesis: on-resin aggregation. As a peptide chain grows during synthesis, it can fold into beta-sheet structures that block further coupling. These building blocks prevent that folding, enabling reliable synthesis of sequences above 40 amino acids at manufacturing scale.

For companies evaluating how to access these capabilities, working with a partner that offers dedicated peptide synthesis services across solid-phase, liquid-phase, and hybrid routes has become the standard approach for advancing complex peptide programs.

Hybrid synthesis strategies have added another dimension. Eli Lilly's team published a hybrid SPPS/LPPS process for tirzepatide in 2021, combining fragment-based solid-phase synthesis with solution-phase assembly. This approach made it possible to manufacture a 39-amino acid dual agonist at kilogram scale, something that linear SPPS alone couldn't deliver with acceptable purity.

How Synthesis Innovation Unlocked Oral Peptide Delivery

Perhaps the most significant shift in the past five years is that peptide drugs can now be taken as pills. Oral peptide delivery was long considered the single biggest barrier to broader clinical adoption. Peptides degrade rapidly in the gastrointestinal tract, and their size makes absorption through the gut lining inefficient.

Oral semaglutide, marketed as Rybelsus, proved this barrier could be overcome. The formulation uses an absorption enhancer (SNAC) that protects the peptide and promotes transcellular transport. The FDA approved the oral formulation, and it's now commercially available alongside injectable versions.

This breakthrough didn't happen in isolation. It required peptide synthesis processes capable of producing API at the purity and consistency levels that oral formulations demand. Tighter impurity control, better analytical characterization, and validated commercial-scale manufacturing all played a role.

Icotrokinra, an oral cyclic peptide targeting IL-23 for psoriasis, is expected to reach FDA review in 2026. If approved, it would further validate that oral delivery is no longer a fundamental limitation for the modality.

Multi-Agonist Programs Are Raising the Manufacturing Bar

The next generation of peptide therapeutics isn't just longer or more complex. It's pharmacologically more ambitious.

Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, is in late-stage clinical trials for obesity and metabolic disease. Molecules like this push peptide synthesis further than previous generations because they combine multiple receptor-binding domains into a single sequence, with modifications that affect both biological activity and manufacturing behavior.

Peptide-drug conjugates are another emerging category where synthesis complexity is rising. These molecules attach cytotoxic payloads to peptide targeting sequences, requiring precise conjugation chemistry on top of the peptide synthesis itself.

For contract manufacturing partners, these programs demand capabilities that go beyond standard SPPS. Process development for multi-agonist peptides involves route optimization across multiple synthetic strategies, advanced purification using preparative HPLC, and analytical methods capable of characterizing novel impurity profiles that existing frameworks don't fully cover.

Regulatory Frameworks Are Catching Up

For most of the modality's history, synthetic peptides fell into a regulatory grey zone. Too complex for standard small-molecule guidelines, but not biologically derived like monoclonal antibodies. That ambiguity created uncertainty for sponsors filing INDs and NDAs.

The EMA's dedicated guideline for synthetic peptides becomes legally effective on June 1, 2026. It covers manufacturing routes, peptide-specific impurity types including stereoisomers and deletion sequences, and comparability requirements. This is the first major regulatory framework designed specifically for how peptide synthesis works and the impurities it generates.

On the FDA side, draft guidance on generic synthetic peptides has clarified impurity identification thresholds and immunogenicity assessment expectations. Together, these developments give drug developers a much clearer path from synthesis through approval.

Where Neuland Laboratories Fits in This Landscape

Neuland Laboratories has built its peptide capabilities around the synthesis and manufacturing challenges described above.

With a dedicated peptide services covering:

• solid-phase, liquid-phase, and hybrid synthesis routes
• three cGMP-certified facilities
• commercial-scale peptide capacity expanding in 2026

Neuland supports pharma and biotech clients from early process development through commercial API supply. Their experience spans sequences from 3 to 40 amino acids, with regulatory approvals from the FDA, EMA, and PMDA that ensure the manufacturing data they generate holds up under global regulatory review.

For teams working on next-generation peptide programs, the synthesis and manufacturing decisions made early shape everything that follows. Get in touch with Neuland's team today.

FAQs

1. How is AI changing the peptide drug discovery process?

AI and computational design platforms are compressing discovery timelines from years to months. Machine learning models now predict sequence stability, receptor binding affinity, and aggregation risk before a single amino acid is coupled. This means fewer failed synthesis campaigns and faster candidate selection, though the manufacturing complexity of the final molecule still requires deep chemistry expertise.

2. What is the difference between synthetic and recombinant peptide production?

Synthetic production builds peptides through chemical coupling of amino acids, either on a solid support or in solution. Recombinant production uses engineered cell lines to express the peptide biologically. Key differences include:

• Synthetic methods offer precise control over non-natural amino acid incorporation and modifications
• Recombinant methods are better suited for very long peptides or proteins above 50 residues
• Regulatory pathways differ, with synthetic peptides filed under NDA/ANDA and recombinant products often following biologic frameworks

3. Are there sustainability concerns with large-scale peptide synthesis?

Yes. Solid-phase synthesis consumes large volumes of organic solvents like DMF and NMP at every coupling and wash step. Industry efforts are now focused on solvent recovery systems, greener coupling reagents, and continuous flow chemistry approaches that reduce waste. These improvements are becoming a practical requirement as production volumes scale to meet GLP-1 demand.

4. How long does it typically take to move a peptide from discovery to first-in-human studies?

Timelines vary by complexity, but most programs take 18 to 30 months from candidate selection to IND filing. Process development, analytical method validation, and GMP manufacturing of clinical supply are the primary time drivers. Working with an experienced CDMO from early development can compress this timeline by avoiding late-stage process changes.